ProCE Banner Activity

UK OPTIMUM/MUKnine: Phase II Trial of Intensified Dara-VRd Consolidation After ASCT in Ultra-High‒Risk Newly Diagnosed Multiple Myeloma and Primary Plasma Cell Leukemia

Slideset Download
Conference Coverage

Intensified consolidation with daratumumab, bortezomib, lenalidomide, and dexamethasone showed clinical benefit in patients with ultra-high‒risk newly diagnosed multiple myeloma and primary plasma cell leukemia in the phase II OPTIMUM/MUKnine trial.

Released: December 15, 2022

Expiration: December 14, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen